Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elidel 1% cream for atopic dermatitis control in infants and impact on childhood asthma
2017-001765-25Phase 4
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pimecrolimus in atopic dermatitis (AD) and asthma (3 arms), sponsored by Novartis. Primary endpoint: Atopic dermatitis disease control over 36 months.
02
Drugs
pimecrolimus
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on 2017-001765-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001765-25.